• 咨询热线
    客服服务热线 13671568941/15317326293
  • 在线咨询
  • 微信客服
    微信客服
  • 公众号
    扫码关注公众号

Senexin C

CAS No. 2375554-02-0

Senexin C ( —— )

产品货号. M35662 CAS No. 2375554-02-0

Senexin C 是一种选择性和具有口服活性的 CDK8/19 抑制剂。Senexin C 显示出强烈的肿瘤富集药代动力学 (PK) 谱和肿瘤药效学 (PD) 标志物反应。Senexin C 抑制 MV4-11 白血病细胞的生长具有良好的耐受性。

纯度: >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
规格 价格/人民币 库存 数量
5MG ¥4551 有现货
10MG ¥6479 有现货
500MG 获取报价 有现货
1G 获取报价 有现货
1 mL x 10 mM in DMSO ¥4513 有现货

生物学信息

  • 产品名称
    Senexin C
  • 注意事项
    本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
  • 产品简述
    Senexin C 是一种选择性和具有口服活性的 CDK8/19 抑制剂。Senexin C 显示出强烈的肿瘤富集药代动力学 (PK) 谱和肿瘤药效学 (PD) 标志物反应。Senexin C 抑制 MV4-11 白血病细胞的生长具有良好的耐受性。
  • 产品描述
    Senexin C is a selective and orally active CDK8/19 inhibitor. Senexin C shows a strong tumor-enrichment pharmacokinetic (PK) profile and tumor-pharmacodynamic (PD) marker responses. Senexin C inhibits the growth of MV4-11 leukemia cells with good tolerability.
  • 体外实验
    Senexin C (compound 20a) exhibits potent CDK8/19 inhibitory activity with high selectivity (IC50s of 56 and 108 nM for 293-NFκB-Luc and MV4-11-Luc cells, respectively).Senexin C (2 μM) shows potency in different kinase assays (IC50= 3.6 nM for CD8/CycC, Kd=1.4 nM for CD8/CycC, Kd=2.9 nM for CDK19/CycC).Senexin C (1 μM, 3 h) shows inhibition on CDK8/19 dependent cellular gene expression.RT-PCR Cell Line:293 cells Concentration:1 μM Incubation Time:3 h Result:Showed inhibition on CDK8/19 dependent cellular gene expression.
  • 体内实验
    Senexin C (2.5 mg/kg, i.v.; 100 mg/kg, p.o.) shows good oral bioavailability.Senexin C (40 mg/kg; p.o.; twice daily for 4 weeks) suppresses the systemic growth of MV4-11 AML with good tolerability.Pharmacokinetic Parameters of Senexin C in eight-week-old female Balb/c mice.Eight-week-old female Balb/c mice ( CT26 tumor mode), 2.5 mg/kg, i.v.(2.5 mg/mL Senexin C solution in 5% dextrose); 100 mg/kg, p.o.(10 mg/mL Senexin C solution in 30% propylene glycol/70% PEG-400 vehicle).Animal Model:eight-week-old female Balb/c mice ( CT26 tumor mode)Dosage:2.5 mg/kg (10 mL/kg of 2.5 mg/mL Senexin C solution in 5% dextrose), 100 mg/kg (10 mL/kg of 10 mg/mL Senexin C solution in 30% propylene glycol/70% PEG-400 vehicle) Administration:2.5 mg/kg, i.v.; 100 mg/kg, p.o.Result:Showed good oral bioavailability.Animal Model:eight-week-old female NSG mice ( AML model) Dosage:40 mg/kg Administration:p.o.; twice daily, 4 weeks Result:Suppressed the systemic growth of MV4-11 AML with good tolerability.
  • 同义词
    ——
  • 通路
    Cell Cycle/DNA Damage
  • 靶点
    CDK
  • 受体
    CDK
  • 研究领域
    ——
  • 适应症
    ——

化学信息

  • CAS Number
    2375554-02-0
  • 分子量
    449.55
  • 分子式
    C28H27N5O
  • 纯度
    >98% (HPLC)
  • 溶解度
    In Vitro:?DMSO 中的溶解度 : 33.33 mg/mL (74.14 mM; ultrasonic and warming and heat to 160°C)
  • SMILES
    N#CC=1C=CC2=NC=CC(NCCC=3C=CC4=CC(=CC=C4C3)C(=O)N5CCN(C)CC5)=C2C1
  • 化学全称
    ——

运输与储存

  • 储存条件
    (-20℃)
  • 运输条件
    With Ice Pack
  • 稳定性
    ≥ 2 years

参考文献

1. Zhang L, et al. A Selective and Orally Bioavailable Quinoline-6-Carbonitrile-Based Inhibitor of CDK8/19 Mediator Kinase with Tumor-Enriched Pharmacokinetics. J Med Chem. 2022; 65(4):3420-3433.?
产品手册
关联产品
  • Roscovitine

    一种有效的选择性 CDK 抑制剂,对 CDK5、Cdc2 和 CDK2 的 IC50 值分别为 0.2 uM、0.65 uM 和 0.7 uM。

  • (R)-Enitociclib

    (R)-Enitociclib, an enantiomer of BAY-1251152, is a CDK9 inhibitor with anticancer activity.

  • AT-7519 trifluoroace...

    一种有效的 CDK2 抑制剂,IC50 为 47 nM;还抑制 CDK1/4/5,IC50 为 190/67/18 nM,并对某些激酶(Aurora A、IR 激酶、MEK、PDK1、c-Abl,IC50>10 uM)表现出选择性。